A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCBY02 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors.
University of Colorado Hospital
Christopher Lieu, MD
Protocol Number: 22-1729
More information available at ClinicalTrials.gov: NCT05496595
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers